

# Effect of dapsone alone and in combination with intracellular antibiotics against the biofilm form of *B. burgdorferi*

Richard Ira Horowitz (✉ [kalachakra108@gmail.com](mailto:kalachakra108@gmail.com))

<https://orcid.org/0000-0002-4952-883X>

**Krithika Murali**

University of New Haven

**Gauri Gaur**

University of New Haven

**Phyllis R. Freeman**

Healing Arts Center

**Eva Sapi**

University of New Haven

---

## Research note

**Keywords:** Lyme disease, *Borrelia burgdorferi*, biofilm, dapsone

**Posted Date:** September 10th, 2020

**DOI:** <https://doi.org/10.21203/rs.3.rs-40534/v2>

**License:** © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

**Version of Record:** A version of this preprint was published at BMC Research Notes on September 29th, 2020. See the published version at <https://doi.org/10.1186/s13104-020-05298-6>.

# Abstract

Objective: Lyme disease is a tick-borne, multisystemic disease caused by *Borrelia burgdorferi*. Standard treatments for early Lyme disease include short courses of oral antibiotics but relapses often occur after discontinuation of treatment. Several studies have suggested that ongoing symptoms may be due to a highly antibiotic resistant form of *B. burgdorferi* called biofilms. Our recent clinical study reported the successful use of an intracellular mycobacterium persister drug used in treating leprosy, diaminodiphenyl sulfone (dapson), in combination therapy for the treatment of Lyme disease. In this *in vitro* study, we evaluated the effectiveness of dapson individually and in combination with cefuroxime and/or other antibiotics with intracellular activity including doxycycline, rifampin, and azithromycin against *Borrelia* biofilm forms utilizing crystal violet biofilm mass, and dimethyl methylene blue glycosaminoglycan assays combined with Live/Dead fluorescent microscopy analyses.

Results: Dapson, alone or in various combinations with doxycycline, rifampin and azithromycin produced a significant reduction in the mass and protective glycosaminoglycan layer and overall viability of *B. burgdorferi* biofilm forms. This *in vitro* study strongly suggests that dapson combination therapy could represent a novel and effective treatment option against the biofilm form of *B. burgdorferi*.

## Introduction

Lyme disease is the number one vector-borne illness in the United States caused by *B. burgdorferi* and transmitted via the bite of Ixodes ticks [1, 2, 3]. Successful frontline treatments for early Lyme disease involve using antibiotics including doxycycline, amoxicillin, cefuroxime axetil, and ceftriaxone [4, 5, 6, 7]. Although standard antibiotic therapy is effective in most cases of early Lyme disease [5], CDC reports suggest that greater than 10% -20% of Lyme patients who have been treated for an *Erythema migrans* (EM) rash, a classical early manifestation of Lyme disease, continue to experience symptoms of fatigue, musculoskeletal pain, and cognitive impairment despite appropriate treatment [8, 9, 10, 11, 12, 13].

Several theories to explain persistent symptoms have been suggested, including immune evasion in privileged sites [14], antigenic variation [15], persistent antigenic stimulation [16], biofilm formation [17, 18] and *B. burgdorferi* persister cells, a highly resistant bacterial form which may protect the bacteria from antibacterial therapy. *B. burgdorferi* can exist in spirochetal, round body forms, intracellularly, as well as in newly discovered biofilm forms [4, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29]. Previous data suggested that standard and some newly discovered antibiotics for Lyme disease can be very effective in eliminating spirochetal, round body, intracellular and antibiotic tolerant persister cells [4, 20, 25, 26, 27] but have little effect on biofilm forms [24, 30]. Persisters are multi-drug tolerant cells present in significant numbers in biofilms [27, 29], and the importance of *Borrelia* biofilms has been highlighted in autopsy tissues from a well-documented Lyme disease patient [31]. Therefore, to successfully treat Lyme disease, there is an urgent need to find an agent or combination of antimicrobial agents which can efficiently eliminate resistant biofilm forms of *B. burgdorferi*.

Dapsone combination therapy (DDS CT) is clinically effective as a novel drug regimen for the treatment of chronic Lyme disease as reported in 100 patients who had previously failed commonly prescribed antibiotic therapies [32]. A recent retrospective study among a larger group of 200 patients also found that dapsone (DDS) combined with other intracellular antibiotics including doxycycline, rifampin, and/or azithromycin was effective in reducing 8 major Lyme disease symptoms [33, 34]. Although dapsone combination therapy was clinically effective, its efficacy against different morphological forms of *B. burgdorferi* in culture had not yet been fully studied. In a previous 2017 study, Feng et al. compared the efficacy of sulfa drugs including dapsone, sulfamethoxazole, sulfachlorpyridazine, and assessed their combinations along with commonly prescribed Lyme antibiotics for their activity against *B. burgdorferi* “persisters” and found that dapsone was the most active drug among the three sulfa drugs [35]. However, this study did not evaluate the effect of any of the sulfa drugs on attached *B. burgdorferi* biofilm. We therefore designed an *in vitro* study using dapsone as a single drug and/or in combination with cefuroxime axetil and/or other antibiotics with intracellular activity including doxycycline, rifampin and azithromycin in order to find the most effective combinations to effectively eliminate resistant biofilm forms of *Borrelia burgdorferi*.

## Methods

### *Bacteria culture conditions*

Low passage isolates of *B. burgdorferi*, B31 strain were obtained from ATCC (#35210, Manassas, VA) and cultured in Barbour-Stoner-Kelly H (BSK-H) media (Sigma, St Louis, MO) supplemented with 6% rabbit serum (Pel-Freez®, Rogers, AR). The stock cultures were maintained in sterile 15ml glass tubes and incubated at 33°C with 5% CO<sub>2</sub> in the absence of antibiotics. Spirochetes for surface attached biofilms were seeded at 5×10<sup>6</sup> cells/ml in 4-well Permanox chamber slides (Thermo Scientific, Waltham, MA) or in 48-well sterile tissue culture plates (BD Falcon, Franklin Lakes, NJ) for 5 days to establish attached biofilm form. Floating spirochetal cells and aggregates from the supernatant were removed to ensure only surface attached biofilms would be analyzed.

### *Antibiotics*

All antibiotics were prepared in standard 1x phosphate buffered saline solution (PBS) and sterilized using 0.2µm filter unit (EMD Millipore, Billerica, MA). As a negative control, 1x PBS was used which was the diluent for antimicrobial compounds studied.

*Crystal violet biofilm, Baclight LIVE/DEAD viability, Dimethylmethylene blue glycosaminoglycan (DMMB) assays*

The effect of the antimicrobial agents on *B. burgdorferi* biofilm mass and viability was evaluated by using a crystal violet assay and *LIVE/DEAD* microscopic analyses respectively as described earlier [30]. The effectiveness of the antibiotic combinations on the *B. burgdorferi* biofilms was also determined by quantifying the biofilm polysaccharide matrix content, glycosaminoglycans (GAG) as described [36].

### *Statistical analysis*

Quantitative results were analyzed using the median value of all the readings from antimicrobial screens in addition to a two-tailed Student's t-test (Microsoft Excel, Redmond, WA, USA). All experiments were performed a minimum of five independent times with at least four replicates per each experimental condition (N=20). Each experiment was repeated by two different scientists (GG and KM) and statistical analyses were conducted independently by a third (ES).

## **Results**

In this study, we compared and evaluated the antimicrobial effect of dapsons along with the other clinically tested antibiotics (doxycycline, rifampin, azithromycin, cefuroxime) on the growth and viability of attached *B. burgdorferi* biofilms using standard crystal violet biofilm mass and dimethylmethylene blue glycosaminoglycan assays combined with BacLight Live/Dead microscopic analysis. As in the previous studies from our group and others [30, 35], we tested two different antibiotic concentrations (10 $\mu$ M and 50 $\mu$ M) against attached *B. burgdorferi* biofilm structures. The 10 $\mu$ M *in vitro* concentration corresponds well to the achievable serum level after administration of the antibiotics tested in this study [37, 38, 39, 40, 41]. Recent studies showed however that higher 50 $\mu$ M concentrations for these antibiotics could be very effective against persister cells [27, 35], therefore this higher concentration was also tested.

First, the effectiveness of the single and combination antibiotic treatments on attached *Borrelia* biofilm was quantified by crystal violet biofilm mass assay after 72h treatments with various antibiotics. The most significant results were achieved with individual and combination treatments with dapsons, as listed in Table 1. The best reduction in biofilm mass by a single antibiotic was achieved with dapsons at 10 $\mu$ M and 50 $\mu$ M concentrations resulting in 69% and 58% residual viability respectively, when compared to the PBS treated control (p value <0.01). Rifampin at both 10 $\mu$ M and 50 $\mu$ M concentrations also resulted in a significant decrease in biofilm mass (76% and 60% respectively, p values <0.01) compared to the PBS treated negative control samples, although not quite as effective as dapsons alone at comparable concentrations. Treatments with other single antibiotics including doxycycline, cefuroxime, and azithromycin were less effective and, in some cases, even increased biofilm size when compared to the PBS treated control (Table 1).

The most effective dual combination was dapsons+doxycycline at both 10 $\mu$ M and 50 $\mu$ M concentrations (68% and 65% residual viability respectively) significantly decreasing biofilm size

compared to the PBS treated control (p value <0.01; Table 1). However, when compared to dapson alone treated samples, this dual combination was not more effective than dapson alone (p value >0.05)

The triple combination treatment of dapson+doxycycline+rifampin (52% residual viability) and quadruple combination of dapson+doxycycline+rifampin+azithromycin (58% residual viability) treatments both at 50µM concentration were the most effective when compared to the PBS treated control (p values < 0.01), however, the effect of three and four drug combinations at 50µM was not significantly better than the 50µM concentration treatments of dapson alone or dapson+doxycycline (p values > 0.05).

Crystal violet biofilm assay only measures the cellular mass (both live or dead) and does not provide information about the viability and the individual sizes of the antibiotic treated biofilm aggregates. Therefore, Live/Dead fluorescent microscopy techniques were used to visualize the effect of the most effective single and combination treatments after 72h with different antibiotics and represented images are presented in Figure 1. Biofilm cultures treated only with PBS show live (green) and compact morphology (Figure 1; Panels A and B). For single and dual antibiotic treatments, the microscopy data were in good agreement with the crystal violet data. For example, it confirmed that single treatment dapson and dual treatment dapson+doxycycline were indeed effective in reducing *Borrelia* biofilm size, resulting in very small aggregates (less than 20 µm aggregates [Figure 1, Panel C]).

However, for triple and quadruple antibiotic treatments, such as dapson+doxycycline+rifampin and dapson+doxycycline+rifampin+azithromycin, the microscopy images suggest a more significant effect of these triple and quadruple combinations than dapson or dapson+doxycycline as demonstrated by very small (less than 10 µm) and disorganized biofilms structures (Figure 1, Panels K and L).

In order to further evaluate the effectiveness of the antibiotics on the attached biofilm form of *B. burgdorferi*, the amount of the protective layers of biofilm polysaccharide matrix of these aggregates were measured using the DMMB glycosaminoglycan (GAG) assay before and after 72h of antibiotic treatments. Biofilms treated with negative control, PBS, showed no reduction in the amounts of GAG, when compared with the untreated biofilm control. The most significant results with the different single and combination of antibiotics are summarized in Table 2. Single antibiotic treatments at 10µM of rifampin and doxycycline were the most effective resulting in 75% and 76% residual GAG amounts compared to the PBS treated control (p value <0.01). However, at 50µM, dapson showed the most significant effects with 68% residual GAG amounts of *Borrelia* biofilm compared to the untreated control (p value <0.01). For combination therapies, dapson+doxycycline+rifampin at 10µM and dapson+doxycycline+rifampin+azithromycin at 50µM were the most effective agents when compared with the untreated control with 69% and 62% residual GAG amounts respectively. The 50µM quadruple combination data were found to be significant not just in comparison to the negative control but to any single treatment result (p value <0.05).

## Discussion

The major findings from this study are that dapson, as a single drug and in combination with doxycycline and doxycycline + rifampin as well as doxycycline + rifampin + azithromycin had the most significant effect in reducing the mass and viability as well the protective mucopolysaccharide layers of *B. burgdorferi* biofilm. These findings might explain at least in part its clinical efficacy seen in recent DDS CT trials [32, 33, 34].

In order to eliminate the most resistant forms of *B. burgdorferi*, there is a need for safe and effective drugs that are able to eliminate all morphological forms of *B. burgdorferi* including attached biofilm forms [24, 30]. Our recent clinical studies reported that DDS combination therapy (DDS with rifampin and a tetracycline [doxycycline, minocycline] and/or a macrolide [azithromycin, clarithromycin] and/or cephalosporin [cefuroxime axetil]) improved symptoms of fatigue, muscle/joint pain, neuropathy, disturbed sleep, cognitive complaints, and sweats and/or flushing [32, 33, 34].

An *in vitro* study [35] evaluated DDS for activity against persisters and found it was not only the most active sulfa drug, but clinically superior to other antibiotics including rifampin, azithromycin, and minocycline. Unfortunately, these researchers did not evaluate DDS combinations against attached *B. burgdorferi* biofilm, the most antibiotic resistant form *in vitro* [24, 30] and a dominant form in a human autopsy study from a Lyme disease patient [31]. Furthermore, a recent mouse model study [42] showed that the biofilm like microcolony and stationary phase planktonic forms (free cells) caused more severe Lyme arthritis with an earlier onset of inflammation and joint swelling than the log phase spirochetes. Therefore, addressing biofilm forms is vital, and for that reason in this study, we added several assays to evaluate dapson alone and in combination on *B. burgdorferi* biofilms. We found that dapson as a single agent is very effective in reducing the attached biofilm forms, and that dapson combination therapy (DDS CT) with a tetracycline, rifampin and/or macrolide had a more significant effect on reducing the mass and viability as well the protective mucopolysaccharide layers of highly resistant *B. burgdorferi* biofilm.

## Conclusion

Results from this study verify that dapson alone and in combination with other antibiotics is effective in reducing the antibiotic resistant biofilm forms of *B. burgdorferi* and support the *in vitro* effectiveness of DDS CT. Two prior published retrospective studies using DDS CT also showed clinical efficacy in relieving eight major Lyme symptoms. Considering the worldwide spread of borreliosis and significant numbers of individuals with persistent Lyme symptoms, prospective randomized trials are urgently required to evaluate the clinical efficacy of DDS CT.

## Limitations

This study evaluated the antibiotic sensitivity of the *B. burgdorferi* B31 laboratory strain and needs to be repeated with other *Bb sensu lato* strains as well to evaluate efficacy.

## Abbreviations

CDC

Centers for Disease Control and Prevention

DDS

Dapsone

DDS CT

Dapsone combination therapy

DMMB

Dimethylmethylene blue glycosaminoglycan

EM

Erythema migrans

GAG

glycosaminoglycan

PBS

Phosphate buffered saline

## Declarations

### Conflict of Interest Statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.

- **Ethics approval and consent to participate:** Not applicable
- **Consent to publish:** Not applicable
- **Availability of data and materials:** University of New Haven, Dr Eva Sapi
- **Competing interests:** None
- **Funding:** MSIDS Research Foundation, LivLyme Foundation, Lyme Navigator Foundation, Lyme Warriors, and National Philanthropic Trust
- **Authors' Contributions:** Dr. Richard Horowitz and Dr. Phyllis Freeman helped design the initial study, and writing/editing of the manuscript. Krithika Murali, Gauri Gaur, and Dr. Eva Sapi from the University of New Haven helped design the study, performed the laboratory experiments, and were equally involved in the writing and editing of this manuscript.

- **Acknowledgements:** The authors thank the MSIDS Research Foundation, LivLyme Foundation, Lyme Navigator Foundation, Lyme Warriors, and National Philanthropic Trust for their support of the research reported in this paper. Microscopes and cameras were donated by [Lymedisease.org](http://Lymedisease.org), the Schwartz Research Foundation, and the Global Lyme Alliance

## Disclaimer

The views expressed are those of Dr Richard Horowitz, and do not represent the views of the Tick-Borne Disease Working Group, HHS or the United States

## References

1. Cook MJ. Lyme borreliosis: a review of data on transmission time after tick attachment. *Int J Gen Med.* 2014;8:1–8. doi:10.2147/IJGM.S73791.
2. Feder HM Jr, Abeles M, Bernstein M, Whitaker-Worth D, Grant-Kels JM. Diagnosis, treatment, and prognosis of erythema migrans and Lyme arthritis. *Clin Dermatol.* 2006;24(6):509–20. doi:10.1016/j.clindermatol.2006.07.012.
3. Kugeler KJ, Farley GM, Forrester JD, Mead PS. Geographic distribution and expansion of human Lyme disease, United States. *Emerg Infect Dis.* 2015;21(8):1455–7. doi:10.3201/eid2108.141878.
4. Donta ST. Tetracycline therapy for chronic Lyme disease. *Clin Infect Dis.* 1997;25(Suppl 1):52–6.
5. Wormser GP, Nadelman RB, Dattwyler RJ, Dennis DT, Shapiro ED, Steere AC, et al. Practice guidelines for the treatment of Lyme disease. *Clin Infect Dis.* 2000;31(Suppl 1):1–14. doi:10.1086/314053134.
6. Eppes SC, Childs JA. Comparative study of cefuroxime axetil versus amoxicillin in children with early Lyme disease. *Pediatr.* 2002;109(6):1173–7.
7. Dattwyler RJ, Wormser GP, Rush TJ, Finkel MF, Schoen RT, Grunwaldt E, et al. A comparison of two treatment regimens of ceftriaxone in late Lyme disease. *Wien Klin Wochenschr.* 2005;117(11–12):393–7.
8. Center of Disease Control and Prevention. Lyme Disease. <https://www.cdc.gov/lyme/stats/humancases.html> (2018). Accessed 20 June 2020.
9. Klempner MS, Hu LT, Evans J, Schmid CH, Johnson GM, Trevino RP, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. *N Engl J Med.* 2001;345(2):85–92. doi:10.1056/NEJM200107123450202.
10. Preac-Mursic V, Wilske B, Gross B, Weber K, Pfister HW, Baumann A, et al. Survival of *B. burgdorferi* in antibioticly treated patients with Lyme borreliosis. *Infect.* 1989;17(6):355–9.
11. Liegner KB, Rosenkilde CE, Campbell GL, Quan TJ, Dennis DT. Culture-confirmed treatment failure of cefotaxime and minocycline in a case of Lyme meningoencephalomyelitis in the United States. In Program and abstracts of the Fifth International Conference on Lyme Borreliosis, Arlington, VA., May 30-June 2, 1992; Bethesda, Md.: Federation of American Societies for Experimental Biology, A11.

12. Liegner KB, Shapiro JR, Ramsay D, Halperin AJ, Hogrefe W, Kong L. Recurrent erythema migrans despite extended antibiotic treatment with minocycline in a patient with persisting *B. burgdorferi* infection. *J Am Acad Dermatol.* 1993;28(2):312–4.
13. Steere AC, Angelis SM. Therapy for Lyme arthritis: Strategies for the treatment of antibiotic-refractory arthritis. *Arthritis Rheum.* 2006;54(10):3079–86.
14. Klempner MS, Noring R, Rogers RA. Invasion of human skin fibroblasts by the Lyme disease spirochete. *B burgdorferi J Infect Dis.* 1993;167(5):1074–81.
15. Zhang JR, Hardham JM, Barbour AG, Norris SJ. Antigenic variation in Lyme disease borreliae by promiscuous recombination of VMP-like sequence cassettes. *Cell.* 1997;89(2):275–85.
16. Jutras BL, Lochhead RB, Kloos ZA, Biboy J, Strle K, Booth CJ, et al. *Borrelia burgdorferi* peptidoglycan is a persistent antigen in patients with Lyme arthritis. *Proc Nat Acad Sci.* 2019;116(27):13498–507. DOI:10.1073/pnas.1904170116.
17. Sapi E, Bastian SL, Mpooy CM, Scott S, Rattelle A, Pabbati N, et al. Characterization of biofilm formation by *B. burgdorferi* *in vitro*. *PLoS ONE.* 2012;7(10):1–11. doi:10.1371/journal.pone.0048277.
18. Sapi E, Balasubramanian K, Poruri A, Maghsoudlou JS, Socarras KM, Timmaraju AV, et al. Evidence of *in vivo* existence of *B. burgdorferi* biofilm in Borrelial lymphocytomas. *Eur J Microbiol Immunol.* 2016;6(1):9–24. doi:10.1556/1886.2015.00049.
19. Brorson Ø, Brorson SH. Transformation of cystic forms of *B. burgdorferi* to normal, mobile spirochetes. *Infect.* 1997;25(4):240–6.
20. Donta ST. Macrolide therapy of chronic Lyme disease. *Med Sci Monit.* 2003;9(11):PI136–42.
21. Murgia R, Cinco M. Induction of cystic forms by different stress conditions in *B. burgdorferi*. *APMIS.* 2004;112(1):57–62. doi:10.1111/j.1600-0463.2004.apm1120110.x.
22. MacDonald AB. Spirochetal cyst forms in neurodegenerative disorders hiding in plain sight. *J Med Hypothesis.* 2006;67(4):819–32.
23. Miklossy J, Kasas S, Zurn AD, McCall S, Yu S, McGeer PL. Persisting atypical and cystic forms of *B. burgdorferi* and local inflammation in Lyme neuroborreliosis. *J Neuroinflamm.* 2008;5(1):40. doi:10.1186/1742-2094-5-40.
24. Sapi E, Kaur N, Anyanwu S, Luecke DF, Datar A, Patel S, et al. Evaluation of *in-vitro* antibiotic susceptibility of different morphological forms of *B. burgdorferi*. *Infect Drug Resist.* 2011;4:97–113. doi:10.2147/IDR.S19201.
25. Feng J, Wang T, Shi W, Zhang S, Sullivan D, Auwaerter PG, et al. Identification of novel activity against *B. burgdorferi* persists using an FDA approved drug library. *Emerg Microbes Infect.* 2014;3(1):1–8. doi:10.1038/emi.2014.53.
26. Feng J, Shi W, Zhang S, Zhang Y. Identification of new compounds with high activity against stationary phase *B. burgdorferi* from the NCI compound collection. *Emerg Microbes Infect.* 2015;4(1):1–15. doi:10.1038/emi.2015.31.

27. Feng J, Auwaerter PG, Zhang Y. Drug combinations against *B. burgdorferi* persists *in vitro*: eradication achieved by using daptomycin, cefoperazone and doxycycline. PLoS One. 2015;10(3):e0117207. doi:10.1371/journal.pone.0117207.
28. Vancová M, Rudenko N, Vaněček J, Golovchenko M, Strnad M, Rego RO, et al. Pleomorphism and viability of the Lyme disease pathogen *B. burgdorferi* exposed to physiological stress conditions: A correlative cryo-fluorescence and cryo-scanning electron microscopy study. Front Microbiol. 2017;8:596. doi:10.3389/fmicb.2017.0059.
29. Rudenko N, Golovchenko M, Kybicova K, Vancova M. Metamorphoses of Lyme disease spirochetes: phenomenon of *B. burgdorferi* persists. Parasit Vectors. 2019;12(1):237. doi:10.1186/s13071-019-3495-7.
30. Theophilus PAS, Victoria MJ, Socarras KM, Filush KR, Gupta K, Luecke DF, et al. Effectiveness of *Stevia rebaudiana* whole leaf extract against the various morphological forms of *B. burgdorferi* *in vitro*. Eur J Microbiol Immunol. 2015;5(4):268–80. doi:10.1556/1886.2015.00031.
31. Sapi E, Kasliwala RS, Ismail H, Torres JP, Oldakowski M, Markland S, et al. The long-term persistence of *Borrelia burgdorferi* antigens and DNA in the tissues of a patient with Lyme Disease. Antibiotics. 2019;8(4):183. doi:10.3390/antibiotics8040183.
32. Horowitz RI, Freeman PR. The use of dapsons as a novel “persister” drug in the treatment of chronic Lyme disease/post treatment Lyme disease syndrome. J Clin Exp Dermatol Res. 2016;7(3):345.
33. Horowitz RI, Freeman PR. Precision medicine: The role of the MSIDS model in defining, diagnosing, and treating chronic Lyme disease/post treatment Lyme disease syndrome and other chronic illness: Part 2. Healthcare. 2018;6(4):129. doi:10.3390/healthcare6040129.
34. Horowitz RI, Freeman PR. Precision medicine: retrospective chart review and data analysis of 200 patients on dapsons combination therapy for chronic Lyme disease/post-treatment Lyme disease syndrome: Part 1. Int J Gen Med. 2019;12:101–19. doi:10.2147/IJGM.S193608.
35. Feng J, Zhang S, Shi W, Zhang Y. Activity of sulfa drugs and their combinations against stationary phase *B. burgdorferi* *in vitro*. Antibiotics (Basel). 2017;6(1):10. doi:10.3390/antibiotics6010010.
36. Tote K, Vanden Berghe D, Maes L, Cos P. A new colorimetric microtitre model for the detection of *Staphylococcus aureus* biofilms. Lett App Microbiol. 2007;46(2):249–54.
37. Zuidema J, Hilbers-Modderman ESM, Merkus FWHM. Clinical pharmacokinetics of dapsons. Clin-Pharmacokinet. 1986;11(4):299–315. <https://doi.org/10.2165/00003088-198611040-00003>.
38. Holmes NE, Charles PGP. Safety and Efficacy Review of Doxycycline. Clin Med Ther. 2009; 1:CMT-S2035. <https://doi.org/10.4137/CMT.S2035>.
39. Garnham JC, Taylor T, Turner P, Chasseaud LF. Serum concentrations and bioavailability of rifampicin and isoniazid in combination. Br J Clin Pharmacol. 1976;3(5):897–902. doi:10.1111/j.1365-2125.1976.tb00644.x.
40. Imamura Y, Higashiyama Y, Tomono K, Izumikawa K, Yanagihara K, Ohno H, et al. Azithromycin exhibits bactericidal effects on *Pseudomonas aeruginosa* through interaction with the outer

membrane. Antimicrob Agents Chemother. 2005;49(4):1377–80. Doi:10.1128/AAC.49.4.1377-1380.2005.

41. Ginsburg CM, McCracken GH Jr, Petruska M, Olson K. Pharmacokinetics and bactericidal activity of cefuroxime axetil. Antimicrob Agents Chemother. 1985;28(4):504–7. doi:10.1128/aac.28.4.504.
42. Feng J, Li T, Yuan Y, Yee R, Bai C, Cai M, et al. Biofilm/persisters/stationary phase bacteria cause more severe disease than log phase bacteria – Biofilm *B. burgdorferi* not only display more tolerance to Lyme antibiotics but also cause more severe pathology in a mouse arthritis model: Implications for understanding persistence, PTLDS and treatment failure. Discov Med. 2019;148:125–238.

## Tables

**Table 1** Effect of different antibiotic treatments on attached *B. burgdorferi* biofilm mass at 10µM and 50µM concentration evaluated with crystal violet biofilm assay after 72h. Table summarizes the mean % of residual viability with ±SD compared to the PBS treated control. Red color indicates the most effective regimens for each group. N=20,

*Abbreviations:* dapsone (DDS), doxycycline (Doxy), rifampin (Rif), cefuroxime (Cef), azithromycin (Az).

Antibiotics Single	10µM Residual % ± %SD	50µM Residual % ± %SD	Antibiotics Dual combinations	10µM Residual % ± %SD	50µM Residual % ± %SD
Control (PBS)	100%	100%	Control (PBS)	100%	100%
DDS	69% ± 5.1	58% ± 4.7	DDS+DOXY	68% ± 5.3	65% ± 4.6
DOXY	107% ± 8.2	103% ± 11.6	DDS+RIF	82% ± 7.6	71% ± 5.6
RIF	76% ± 4.3	60% ± 8.9	DDS+AZ	106% ± 9.1	93% ± 7.3
CEF	109% ± 8.6	102% ± 9.5	DDS+CEF	83% ± 7.3	101% ± 10.3
AZ	101% ± 7.4	91% ± 7.9	DOXY+RIF	73% ± 5.8	74% ± 6.5
Antibiotics Triple combinations	10µM Residual % ± %SD	50µM Residual % ± %SD	Antibiotics Quadruple combinations	10µM Residual % ± %SD	50µM Residual % ± %SD
Control (PBS)	100%	100%	Control (PBS)	100%	100%
DDS+DOXY+RIF	78% ± 5.8	52% ± 4.1	DDS+DOXY+RIF+CEF	72% ± 5.2	79% ± 6.2
DDS+DOXY+CEF	65% ± 4.2	60% ± 8.8	DDS +DOXY+RIF+AZ	78% ± 5.4	58% ± 3.5
DDS+DOXY+AZ	80% ± 7.7	72% ± 6.5	DDS +RIF+AZ+CEF	81% ± 6.8	68% ± 5.5
DDS+RIF+AZ	69% ± 4.2	77% ± 8.5	DOX+RIF+AZ+CEF	98% ± 8.5	82% ± 5.1
DDS+RIF+CEF	70% ± 5.6	62% ± 5.6			

**Table 2** Effect of different antibiotic treatments on attached *B. burgdorferi* biofilm glycosaminoglycan (GAG) content at 50µM concentration evaluated with Dimethylmethylene Blue Assay for Glycosaminoglycan after 72h treatments. The table summarizes that mean % of the residual GAG amounts with ±SD compared to the PBS treated control. Red color indicates the most effective regimens for single and combination antibiotics.

N=20

*Abbreviations:* dapsone (DDS), doxycycline (Doxy), rifampin (Rif), cefuroxime (Cef), azithromycin (Az).

Antibiotics	10µM GAG % ± %SD	50µM GAG % ± %SD
Control (PBS)	100%	100%
DDS	79% ± 5.8	68% ± 3.6
DOXY	76% ± 4.2	73% ± 7.2
RIF	75% ± 6.3	70% ± 5.8
CEF	78% ± 5.2	76% ± 7.4
AZ	82% ± 6.6	79% ± 8.2
DDS+DOXY	70% ± 8.2	69% ± 5.3
DDS+DOXY+RIF	69% ± 4.2	70% ± 7.3
DDS+DOXY+RIF+AZ	75% ± 6.8	62% ± 5.4

## Figures




Figure 1

Representative Live/Dead images of the attached *B. burgdorferi* biofilms following treatment with different antimicrobial agents at 10 $\mu$ M. Biofilms were stained with SYBR Green I and PI as outlined in the Material and Methods and representative images were taken at 100X magnification. Scale bar: 100  $\mu$ m.